SAQLANGAN HAYDASH FRAKSIYASI BILAN YURAK YETISHMOVCHILIGIDA SAKUBITRIL-VALSARTAN TERAPIYASINING TA’SIRI
##article.subject##:
Saqlangan qon haydash fraksiyasi bilan yurak yetishmovchiligi (SQHFSYuY), sakubitril, valsartan, NYHA, sistolik qon bosimi (SQB).##article.abstract##
Dolzarbligi: So‘nggi 20 yil ichida yurak yetishmovchiligi holatlari soni dunyo bo‘ylab ikki baravar oshganligi qayd qilingan. Saqlangan qon haydash fraksiyasi bilan yurak yetishmovchiligi (SQHFSYuY) keng tarqalgan kasallik bo‘lib, uning ko‘lami aholi salomatligi uchun haqiqiy muammoga aylanib bormoqda. Ushbu kasallikni samarali davolash usullari hali mavjud yemas, bu esa uni o‘rganishni dolzarb muammoligini tasdiqlaydi. Materiallar va usullar: Tadqiqot ishi Samarqand viloyati kardiologiya markazida o‘tkazildi. Tadqiqot saqlangan qon haydash fraksiyasi bilan yurak yetishmovchiligi (SQHFSYuY) aniqlangan 48 bemorni o‘z ichiga olgan bo‘lib, davolanishdan oldin va keyin bemorlarning asosiy klinik va laboratoriya ko‘rsatkichlari taqqoslandi. Statistik ma’lumotlarni qayta ishlash SPSS dasturi 28.0 versiyasi yordamida amalga oshirildi, ko‘rsatkichlar farqi P < 0.05 darajasida statistik jihatdan ahamiyatli hisoblandi. Natijalar: Tadqiqotga kiritilgan bemorlar ikki guruhga ajratildi: 1-guruh (n=24): sakubitril/valsartan berildi. 2-guruh (n=24): faqat valsartan bilan davolash olib borildi. 16 haftalik davodan so‘ng sakubitril/ valsartan olgan bemorlarda klinik va laboratoriya parametrlarining sezilarli yaxshilanishi qayd etildi: sistolik qon bosimining (SQB) o‘rtacha pasayishi sakubitril/ valsartan guruhida -10.3 ± 1.0 mm.sim.ust, valsartan guruhida - 6.4 ± 0.9 mm.sim.ust ni tashkil etdi (P < 0,05). NYHA bo‘yicha YuYe funksional sinfining yaxshilanishi birinchi guruhdagi bemorlarning 63 foizida, ikkinchi guruhdagi 42% (P < 0.05) da kuzatilgan. Xulosa: Olingan natijalar SYuYe mavjud bemorlarda sakubitril/ valsartan bilan kompeks terapiya valsartan bilan monoterapiyaga qaraganda samaraliroq ekanligini tasdiqlaydi. Sakubitril/ valsartan bilan davolash qon bosimini va gospitalizatsiya qilish chastotasini sezilarli darajada kamaytirdi, shuningdek bemorlarning funksional holatini yaxshiladi. Bu bizga ushbu terapiyani SYuYe bilan og‘rigan bemorlarni davolashda, ayniqsa gipotenziv vositalarga rezistentlik kuzatilgan gipertenziya holatlarida samarali davo usuli sifatida qo‘llashga imkon beradi.
Библиографические ссылки
Agababyan I. R, Nizamova N. G. Clinical and prognostic features of patients with unstable angina and chronic heart failure with preserved left ventricular ejection fraction results of conservative treatment. Web of Medicine: Journal of Medicine, Practice and Nursing. 2025; 3 (1): 386-88. DOI: 616.124-008.46:615.22
Agababyan I. R, Nizamova N. G. Исследование Эффективности Сакубитрил/Валсартана у Пatsiентов с Сердечной Недостаточностью: Результаты Кардиологического Центра Самаркандского Региона. New Day in Medicine (2023-2024 гг.) 2025; 3 (77): 675-83 ISSN 2181-712X.
Agababyan I. R, Nizamova N. G. Nizamov X.SH. Xasandjanova F.O. Анализ Факторов Риска Развития Неблагоприятных Событий у Пatsiентов с Декомпенсatsiей Хронической Сердечной Недостаточности. Вестник Ассоциatsiи Пульмонологов Центральной Азии 2025; 2 (7) 93-96. ISSN 2181-4988
Cheng RK, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. American Heart Journal. 2014;168(5):721–30. DOI: 10.1016/j.ahj.2014.07.008.
Damman K, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Failure. 2018;6(6):489–98. DOI: 10.1016/j.jchf.2018.02.004.
Fu S, et al. Effects of Sacubitril-Valsartan in HFpEF Patients Undergoing Peritoneal Dialysis. Frontiers in Medicine. 2021;8:657067. DOI: 10.3389/fmed.2021.657067.
Ho JE, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions. Circulation. 2019;140(5):353–65. DOI: 10.1161/CIRCULATIONAHA.118.039136.
Jackson AM, et al. Sacubitril–valsartan for resistant hypertension in HFpEF. European Heart Journal. 2021;42(36):3741–3752. DOI: 10.1093/eurheartj/ehab499.
McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371:993–1004. DOI: 10.1056/NEJMoa1409077.
Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128.
Solomon SD, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. The Lancet. 2012;380:1387–95. DOI: 10.1016/S0140-6736(12)61227-6.
Solomon SD, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail 2017;5:471–482.
Tadic M, et al. The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more? Heart Failure Reviews. 2018;23:631–639. DOI: 10.1007/s10741-018-9701-4.
Upadhya B, et al. Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. Heart Failure Reviews. 2018;23:609–29. DOI: 10.1007/s10741-018-9714-z.
Williams B , et al. British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol,and doxazos into determine the optimal treatment for drug resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.Lancet2015; 386:2059–2068.
Cornuault L., et al. Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction: What are the Experimental Proofs? Front Physiol. 2022 Jul 8;13:906272. doi: 10.3389/fphys.2022.906272. PMID: 35874523; PMCID: PMC9304560.
. Schiattarella GG, et al. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc Res. 2021 Jan 21;117(2):423-434. doi: 10.1093/cvr/cvaa217. PMID: 32666082; PMCID: PMC8599724.
